Michael Schmitz
Stock Analyst at Guggenheim
(3.14)
# 1,215
Out of 5,182 analysts
8
Total ratings
71.43%
Success rate
112.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $19.15 | -73.89% | 1 | Nov 14, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $26.64 | +61.41% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $44.65 | +0.78% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $131.67 | -37.72% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $10.29 | +288.73% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.31 | - | 1 | Jan 3, 2023 | |
| APC ARKO Petroleum | Initiates: Buy | $85 | $18.11 | +369.35% | 1 | Dec 19, 2016 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $19.15
Upside: -73.89%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $26.64
Upside: +61.41%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $44.65
Upside: +0.78%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $131.67
Upside: -37.72%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $10.29
Upside: +288.73%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.31
Upside: -
ARKO Petroleum
Dec 19, 2016
Initiates: Buy
Price Target: $85
Current: $18.11
Upside: +369.35%